BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection

Lymphoma

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Lancet Haematol

Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ

doi: 10.1016/S2352-3026(26)00045-1

Multiple Myeloma (MM)

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Ann Hematol

Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, Krauth MT, Knop S, Winder T, Steiner N

doi: 10.1007/s00277-026-07140-8

Multiple Myeloma (MM)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Am J Hematol

Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Martínez-Lopez J, Kastritis E, Chng WJ, Kapoor P, Dave M, Bal S, Garderet L, Corraes AMS, Riedhammer C, Steinbrunn T, Corona M, Nagarajan C, Einsele H, Martin T, Krishnan A, Lin Y

doi: 10.1002/ajh.70376

Further Publications

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis

JAMA Oncol

Tomasik J, Tix T, Alhomoud M, Yamshon S, Cliff ERS, Iacoboni G, Cordas Dos Santos DM, Merz M, Subklewe M, Gafter-Gvili A, Usmani SZ, Salles G, Perales MA, Basak GW, Rejeski K, Shouval R

doi: 10.1001/jamaoncol.2026.1859

Multiple Myeloma (MM)

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

Am J Hematol

Ludwig H, Terpos E, Gay F, van de Donk NWCJ, Bernhard S, Engelhardt M, Cook G, Schjesvold F, Einsele H, Jackson G, Pawlyn C, Mateos MV, Zweegman S, Schreder M, Beksaç M, Driessen C, Ocio EM, Popat R, Rasche L, Touzeau C, Musto P, Broijl A, Dimopoulos M, Hajek R, Boccadoro M, Sonneveld P

doi: 10.1002/ajh.70397

Multiple Myeloma (MM)

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Leuk Lymphoma

Leitner T, Oelschläger L, Henriquez Mosquera F, Schaefers C, Leypoldt L, Weisel K, von Bubnoff N, Rückert M, Kimmich C, Ahmed H, Vorwerk J, Khandanpour C

doi: 10.1080/10428194.2026.2699285

Multiple Myeloma (MM)

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis

Am J Hematol

Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann SM, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R

doi: 10.1002/ajh.70297

Leukemia

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Leuk Lymphoma

Alhajahjeh A, Beke KE, Grimshaw AA, Aguirre LE, Mina A, Podoltsev NA, Mendez L, Stahl M, Zeidan AM, Bewersdorf JP

doi: 10.1080/10428194.2026.2682397

Genitourinary Cancer

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Int J Cancer

Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM

doi: 10.1002/ijc.70525

Related content

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials